KITLG

Across TCGA pan-cancer cohorts, KITLG Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KITLG data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher KITLG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KITLG expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

COAD, BLCA, and UCEC are the cancer types where KITLG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	16	view →
BLCA	OS	Median	All	0.193	0.720	.002	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →
LUAD	OS	Median	All	0.212	0.672	.025	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.670	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KITLG–COAD (OS)

Open the COAD breakdown →